Report Reveals Major Gaps in Cancer Drug Price Controls

A recent report by the Committee on Petitions has highlighted critical gaps in the pricing mechanisms for cancer drugs in India. The findings, part of the committee’s 163rd report submitted to Parliament, indicate that a significant number of oncology medications are not covered by existing price control regulations.

The report notes that while the National List of Essential Medicines was updated in 2022 to include 63 anti-cancer medicines, up from 40 in 2011, many essential drugs remain outside the scope of the Drugs (Prices Control) Order (DPCO) of 2013. This regulatory omission has resulted in high and often unaffordable prices, limiting access for numerous patients.

“This regulatory non-inclusion has led to excessive and often unaffordable pricing, thereby limiting access for a large section of the patient population,” the report stated. In response, the committee urged the government to take immediate action to broaden the DPCO’s coverage to encompass a wider range of cancer treatments. Additionally, it recommended that comprehensive market assessments be regularly conducted to monitor drug pricing and availability trends.

The report also raised concerns regarding the quality of generic drugs available in the country. Many medical professionals are hesitant to prescribe generics due to a lack of certification under the World Health Organization’s Good Manufacturing Practices. Ensuring the quality of these alternatives is vital for patient trust and access to affordable medications.

While the current framework allows for accelerated access to new cancer drugs, the report identified several barriers that hinder timely patient access. Issues such as regulatory delays, inadequate domestic research and development, and pricing constraints were highlighted. The committee recommended enhancing domestic research infrastructure, prioritizing value-based approvals, and streamlining regulatory pathways to support the indigenous development of innovative oncology therapies.

Furthermore, the report pointed out a disconnect between private sector medical institutions and the Union Ministry of Health and Family Welfare regarding the approval processes for clinical trials. To improve collaboration, the committee suggested that both sectors work together to maximize benefits for patients.

The committee also advocated for platforms like the India Cancer Research Consortium to publish annual performance reports. These reports should document the extent to which research outputs have been translated into clinical practice. The report emphasized the need for mechanisms that systematically track patient outcomes and assess the cost-effectiveness of treatment guidelines to inform evidence-based policymaking.

In conclusion, the findings of the Committee on Petitions underscore the urgent need for reforms in the pricing and approval processes for cancer drugs in India. By addressing these gaps, the government can enhance patient access to essential medications and improve health outcomes across the country.